GE HealthCare Technologies GEHC · NASDAQ
$69.76 +0.27% (+$0.19)
Summary
53 / 100 · Bulios Score
What speaks for it
- It has been profitable 6 years in a row.
- It beat profit estimates 7 times in the last 8 quarters.
What to watch
None of the indicators we track raises a caution right now.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Fairly pricedBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 19.8 USD for 1 USD of yearly profit. Over the last five years it was 18.1 USD on average.
Valuation in detailIs it growing?
It is shrinkingRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 3.7% a year over 5 years. Over the last 3 years it grew by 4.0% a year. For the next fiscal year analysts expect revenue to grow by 5.3%. Earnings per share grew by 2.5% a year over the last 3 years.
Growth in detailDoes it make money?
ReasonablyWhere 100 USD of revenue goes
- Cost of sales 57 USD
- Research and development 6.5 USD
- Sales and administration 24 USD
- Taxes and other 4.8 USD
- Net profit 7.9 USD
Net profit, industry median (Medical - Devices) 6.9 USD
Out of every 100 USD of revenue, 7.9 USD is left as net profit.
Profitability in detailIs it financially healthy?
Debt is a burdenRepaying all its debt would take 11.3 years of free cash flow. Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
Small, safe- Yield
- 0.20%
- Paid out of profit
- 4.0%
- Raised in a row
- 1 year
You receive $0.14 per share a year. The company covers the payout with ease.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 11
- Hold 8
- Sell 0
Today's price within the analysts' price targets
The average target of $79.92 is 15% above today's price. 58% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
- Imaging Segment 61%
- PCS Segment 20%
- PDx Segment 19%
By region
- Other Countries 46%
- UNITED STATES 44%
- CHINA 9.8%
Imaging Segment brings in 61% of revenue. PDx Segment grew fastest, by 12% a year.
Segments in detail